Previous 10 | Next 10 |
National reimbursement decision for Optune® in Germany anticipated in 2020 Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s...
Editor's note: Seeking Alpha is proud to welcome Chen Yang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's note: Seekin...
Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without solid implementation can do more harm than good. This is especially true among growth stocks, since these ...
The following slide deck was published by NovoCure Limited in conjunction with this Read more ...
Shares of NovoCure ( NVCR ) have risen over fivefold since introducing this medical device story to readers in 2016. The stock price is up over 50% since my December update piece suggested investors take advantage of a "solid buying opportunity" caused by flat prescription growth in Q3. ...
Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a Q&A s...
The FDA approves Novocure's (NASDAQ: NVCR ) NovoTTF-100L System, combined with Eli Lilly's (NYSE: LLY ) Alimta (pemetrexed) and platinum-based chemo, for the first-line treatment of locally advanced or metastatic malignant pleural mesothelioma (MPM). More news on: NovoCure Limited, ...
Safety First: NASCAR driver Johanna Long and her helmet (Image Credit: Gearheads ) Bulletproof Investing: Week 78 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. T...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD ) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Pr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...